328 related articles for article (PubMed ID: 23454865)
1. Overcoming pharmacologic sanctuaries.
Cory TJ; Schacker TW; Stevenson M; Fletcher CV
Curr Opin HIV AIDS; 2013 May; 8(3):190-5. PubMed ID: 23454865
[TBL] [Abstract][Full Text] [Related]
2. The Importance of Tissue Sanctuaries and Cellular Reservoirs of HIV-1.
Kalada W; Cory TJ
Curr HIV Res; 2022 Aug; 20(2):102-110. PubMed ID: 34961449
[TBL] [Abstract][Full Text] [Related]
3. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
5. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients.
Solas C; Lafeuillade A; Halfon P; Chadapaud S; Hittinger G; Lacarelle B
Antimicrob Agents Chemother; 2003 Jan; 47(1):238-43. PubMed ID: 12499197
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 Sanctuary Sites-the Role of Membrane-Associated Drug Transporters and Drug Metabolic Enzymes.
Whyte-Allman SK; Bendayan R
AAPS J; 2020 Sep; 22(5):118. PubMed ID: 32875457
[TBL] [Abstract][Full Text] [Related]
7. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Pierson T; McArthur J; Siliciano RF
Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
[TBL] [Abstract][Full Text] [Related]
8. The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition.
Michaud V; Bar-Magen T; Turgeon J; Flockhart D; Desta Z; Wainberg MA
Pharmacol Rev; 2012 Jul; 64(3):803-33. PubMed ID: 22759796
[TBL] [Abstract][Full Text] [Related]
9. Antiretroviral drug concentrations in semen of HIV-1 infected men.
Taylor S; Pereira AS
Sex Transm Infect; 2001 Feb; 77(1):4-11. PubMed ID: 11158684
[TBL] [Abstract][Full Text] [Related]
10. The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV-Infected Persons.
Fletcher CV; Podany AT; Thorkelson A; Winchester LC; Mykris T; Anderson J; Jorstad S; Baker JV; Schacker TW
Clin Pharmacol Ther; 2020 Nov; 108(5):971-975. PubMed ID: 32385902
[TBL] [Abstract][Full Text] [Related]
11. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues.
Fletcher CV; Staskus K; Wietgrefe SW; Rothenberger M; Reilly C; Chipman JG; Beilman GJ; Khoruts A; Thorkelson A; Schmidt TE; Anderson J; Perkey K; Stevenson M; Perelson AS; Douek DC; Haase AT; Schacker TW
Proc Natl Acad Sci U S A; 2014 Feb; 111(6):2307-12. PubMed ID: 24469825
[TBL] [Abstract][Full Text] [Related]
12. Persistent HIV-1 replication maintains the tissue reservoir during therapy.
Lorenzo-Redondo R; Fryer HR; Bedford T; Kim EY; Archer J; Pond SLK; Chung YS; Penugonda S; Chipman J; Fletcher CV; Schacker TW; Malim MH; Rambaut A; Haase AT; McLean AR; Wolinsky SM
Nature; 2016 Feb; 530(7588):51-56. PubMed ID: 26814962
[TBL] [Abstract][Full Text] [Related]
13. Review: HIV-1 phylogeny during suppressive antiretroviral therapy.
Bale MJ; Kearney MF
Curr Opin HIV AIDS; 2019 May; 14(3):188-193. PubMed ID: 30882485
[TBL] [Abstract][Full Text] [Related]
14. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration.
Eggers C; Hertogs K; Stürenburg HJ; van Lunzen J; Stellbrink HJ
AIDS; 2003 Sep; 17(13):1897-906. PubMed ID: 12960822
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of HIV Cure: Site of Action.
Devanathan AS; Cottrell ML
Clin Pharmacol Ther; 2021 Apr; 109(4):841-855. PubMed ID: 33540481
[TBL] [Abstract][Full Text] [Related]
16. Roundtable report: importance of antiretroviral drug concentrations in sanctuary sites and viral reservoirs.
Reddy YS; Kashuba A; Gerber J; Miller V;
AIDS Res Hum Retroviruses; 2003 Mar; 19(3):167-76. PubMed ID: 12689408
[No Abstract] [Full Text] [Related]
17. Drug uptake transporters in antiretroviral therapy.
Minuesa G; Huber-Ruano I; Pastor-Anglada M; Koepsell H; Clotet B; Martinez-Picado J
Pharmacol Ther; 2011 Dec; 132(3):268-79. PubMed ID: 21816170
[TBL] [Abstract][Full Text] [Related]
18. Combating the HIV reservoirs.
van Marle G; Church DL; van der Meer F; Gill MJ
Biotechnol Genet Eng Rev; 2018 Apr; 34(1):76-89. PubMed ID: 29781356
[TBL] [Abstract][Full Text] [Related]
19. Eradication of HIV from Tissue Reservoirs: Challenges for the Cure.
Rose R; Nolan DJ; Maidji E; Stoddart CA; Singer EJ; Lamers SL; McGrath MS
AIDS Res Hum Retroviruses; 2018 Jan; 34(1):3-8. PubMed ID: 28691499
[TBL] [Abstract][Full Text] [Related]
20. Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art.
Fiandra L; Capetti A; Sorrentino L; Corsi F
J Neuroimmune Pharmacol; 2017 Mar; 12(1):17-30. PubMed ID: 27832401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
